SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
PDS Biotechnology closed a Securities Purchase Agreement with YA II PN, LTD. on June 15, 2026, issuing a $6,000,000 promissory note convertible into common stock and a warrant to purchase 2,158,274 shares at $1.1824/share, plus establishing a $50,000,000 at-the-market offering program. This private placement under Section 4(a)(2) and Regulation D Rule 506 materially dilutes shareholder equity and voting power.
View raw filing on EDGAR →PDS Biotechnology redeemed and fully prepaid all outstanding Senior Secured Convertible Debentures issued under a Securities Purchase Agreement dated April 30, 2025, paying 103% of principal plus accrued interest. This debt retirement and capital restructuring materially affects the company's financial obligations and capital structure.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Ollie's Bargain Outlet's June 11, 2026 annual meeting of stockholders, including the election of ten directors, advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. The detailed vote tallies for each director and each proposal are the core content of a shareholder_vote_results event.
View raw filing on EDGAR →Kimco Realty issued $600 million in 3.50% Exchangeable Senior Notes due 2031 (with an additional $75 million option exercised, totaling $675 million) under Section 4(a)(2) and Rule 144A, with up to 23.6 million shares of common stock potentially issuable upon exchange. The exchangeable feature, substantial dilutive potential, and capital-raising nature of this unregistered transaction are material to investors' assessment of ownership dilution and the company's financing activities.
View raw filing on EDGAR →Viatris entered into an underwriting agreement to issue €650 million in Senior Notes due 2033 at 4.250%, with closing expected June 17, 2026. This is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, but does not fit the more specific taxonomy categories (not a dilutive equity issuance, not M&A, not a restatement or covenant breach). The disclosure is appropriately classified as other_material rather than dilutive_issuance, which applies to equity securities.
View raw filing on EDGAR →Momentus consummated a registered direct offering of 1,851,852 shares of Class A common stock at $13.50 per share on June 15, 2026, raising approximately $25.0 million in gross proceeds. The offering included lock-up restrictions and warrant issuance to the placement agent, materially diluting existing shareholders and affecting the company's capital structure.
View raw filing on EDGAR →ING announced the appointment of Hilde Garssen to the Management Board Banking as chief human resources officer (CHRO), effective 1 September 2026. This is a clear executive appointment to a senior leadership role on the Management Board. The disclosure notes that the CHRO role has been elevated to the Management Board level, reflecting strategic importance, and the appointment has been approved by the European Central Bank, indicating material governance significance.
View raw filing on EDGAR →The press release's primary disclosure is the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets. The release states "Ongoing evaluation of our corporate team and issuer status has provided the opportunity to further enhance our c-suite effectiveness and to optimize our public markets efficiency with the addition of Mika Grasso as co-CEO." This is a material executive appointment affecting the registrant's leadership structure and governance, with detailed biographical information provided. While the release also discusses corporate strategy and drug development programs, the headline and substantive focus is the executive appointment.
View raw filing on EDGAR →The press release discloses a U.S. Department of Energy order mandating that TransAlta's Centralia Unit 2 remain available for operation for an additional 90 days through September 13, 2026. This is a regulatory directive affecting the operational status of a material asset. While not fitting a discrete named event type (not M&A, not a workforce reduction, not litigation), it is clearly an operational/regulatory matter that would affect investor assessment of the company's generation capacity and compliance obligations. The materiality stems from the operational constraint imposed on a significant power generation facility.
View raw filing on EDGAR →This press release announces a key operational milestone: receipt of the first custom-built underground haul truck from Young's Machine Company and a new equipment supply agreement. The disclosure demonstrates material progress toward production at Anfield's uranium-vanadium mines (Velvet-Wood, JD-8, Slick Rock) and reflects the company's advancement of its hub-and-spoke production model. While not a discrete M&A transaction, debt issuance, or financial result, this operational achievement—securing critical mining equipment and establishing a supply partnership—would affect a reasonable investor's assessment of the company's ability to execute its development strategy and timeline.
View raw filing on EDGAR →Legend Biotech announced clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T therapy, presented at EHA 2026. Phase 1 trial results demonstrated 100% ORR and 83.3% CR at dose level 2 with a favorable safety profile, no dose-limiting toxicities, and supporting pharmacokinetic/integration data for the TaVec platform.
View raw filing on EDGAR →The disclosure describes a reverse stock split (1-for-6 ratio) approved by stockholders and implemented via amendment to the Certificate of Incorporation, effective June 11, 2026. While this is a structural capital event affecting all shareholders proportionately, it does not fit neatly into the standard taxonomy categories. The event is material because it affects share count, trading mechanics, and investor holdings, but it is primarily a routine corporate action rather than a sign of financial distress or operational change. Classified as "other_material" because reverse splits, though significant, are administrative capital structure adjustments distinct from the more acute events (impairment, covenant breach, delisting risk) that typically signal material financial or operational trouble.
View raw filing on EDGAR →Safety Insurance entered Amendment No. 7 to its revolving credit facility, doubling the committed amount from $50 million to $100 million and extending the maturity date to June 9, 2031, materially expanding the company's liquidity and extending its debt maturity profile.
View raw filing on EDGAR →The exhibit announces the departure of Cynthia L. Paul from Allot's Board of Directors, effective June 15, 2026. She served since November 2022 and supported the company through operational transformation and financial strengthening. This is a clear board member departure disclosure, matching the exec_departure category. The materiality is supported by her tenure and the company's emphasis on her role during a critical transformation period, though the departure is characterized as voluntary due to other business demands rather than adverse circumstances.
View raw filing on EDGAR →Gilat has entered into a definitive agreement to acquire the majority of Comtech's Satellite & Space Communications segment for $157.5 million in cash. The transaction is described as "transformative," is expected to exceed $700 million in projected annual revenue, and has been unanimously approved by both boards. This is a material acquisition that would significantly affect investor assessment of Gilat's scale, strategic direction, and financial position.
View raw filing on EDGAR →Tower Semiconductor and IQE announced a multi-year supply agreement for Indium Phosphide epiwafers supporting Tower's silicon photonics platforms for AI-driven data center infrastructure, with minimum purchase and volume commitments. The agreement also resolves all prior IP disputes through a royalty-free patent license. This is a material strategic partnership and supply arrangement affecting Tower's product roadmap and competitive positioning in high-growth optical connectivity markets, but does not fit the specific categories of M&A, debt, equity issuance, or other defined event types.
View raw filing on EDGAR →Nutrien has disclosed an unsolicited mini-tender offer by Ocehan LLC targeting approximately 0.02% of outstanding shares at a 24.91%–26.13% discount to market price. While mini-tender offers are typically small and routine, this disclosure is material because it alerts shareholders to a below-market offer and warns of potential investor confusion—a concern flagged by both the CSA and SEC. The company's explicit caution and recommendation against the offer, combined with the regulatory context, makes this a material shareholder communication that would affect investor decision-making, even though the offer itself is small and unsolicited.
View raw filing on EDGAR →Woodside issued a formal announcement denying media speculation about a potential transaction with Exxon Mobil Corporation, explicitly stating it is "not aware of any proposal and confirms it is not in discussions" regarding such a transaction. While this is a denial rather than disclosure of an actual M&A event, the announcement addresses material market speculation about a potential change of control or major acquisition that would significantly affect investor assessment. The company's need to issue a formal denial through its Disclosure Committee indicates the speculation was sufficiently material to warrant official clarification, though the event itself (a denial of rumors) does not fit neatly into the M&A activity category since no actual transaction is being disclosed.
View raw filing on EDGAR →The 6-K discloses Week 182 data from the completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide), demonstrating sustained efficacy and safety in hypoparathyroidism over three-and-a-half years. This is a material clinical milestone—positive Phase 3 trial results supporting regulatory approval and commercial viability—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). It is a material operational/clinical development that would affect investor assessment of the product's regulatory and commercial prospects.
View raw filing on EDGAR →Toyota Motor Corporation announces the completion of the sale of all 74,100,604 shares of Toyota Industries Corporation (24.66% ownership) and expects to record gains on sale of shares of subsidiaries and affiliates of 1,206.3 billion yen (non-consolidated) and 576.9 billion yen (consolidated estimate) for fiscal year ending March 31, 2027. This is a material divestiture of a significant equity stake with substantial financial impact, but does not fit the specific categories of ma_activity (which typically covers acquisitions, mergers, or changes of control) or other named event types. The transaction is a completed asset sale/divestiture with material gain recognition.
View raw filing on EDGAR →Birkenstock Group B.V. & Co. KG, a wholly-owned subsidiary of Birkenstock Holding plc, launched an offering of €900 million in aggregate principal amount of senior notes due 2033. The proceeds will be used to redeem existing €428.5 million senior notes due 2029, finance share repurchases, refinance other indebtedness, and pay transaction fees.
View raw filing on EDGAR →The company announced a discretionary share repurchase program of up to $500 million and amendments to its term and revolving facilities agreement, including the release of liens securing existing debt obligations, in connection with separately announced refinancing transactions.
View raw filing on EDGAR →Peabody Energy entered into two material definitive surety bond facility agreements totaling A$700 million in commitments with Liberty Mutual and Swiss Re on June 12, 2026, to replace existing cash collateralized programs and amended its revolving credit facility. The concurrent termination of prior Transaction Support Agreements and related collateral arrangements allows for reduction of pledged collateral, materially affecting the company's capital structure and liquidity position.
View raw filing on EDGAR →Lexeo Therapeutics announced material regulatory updates regarding LX2006 for Friedreich ataxia cardiomyopathy, including pivotal study design to support accelerated approval pathway. This represents significant clinical and regulatory progress for the company's gene therapy candidate.
View raw filing on EDGAR →The filing discloses Canopy Growth Corporation's financial results for its fiscal fourth quarter ended March 31, 2026, via a press release attached as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →Alkermes announced the grant of orphan drug designations by the FDA and European Commission for alixorexton in idiopathic hypersomnia and narcolepsy indications, providing significant regulatory and commercial benefits including extended market exclusivity, tax credits, and reduced approval timelines.
View raw filing on EDGAR →Fox Corporation announced entry into a definitive agreement to acquire Roku, Inc., disclosed via joint press release on June 15, 2026. This is a material acquisition transaction that would substantially affect the registrant's business, assets, and strategic direction. The disclosure explicitly references the definitive agreement and upcoming investor conference call, making the M&A activity the central event disclosed in this Item 7.01 filing.
View raw filing on EDGAR →Item 3.02 discloses an unregistered sale of equity securities—specifically, the issuance of "Consideration Shares to the Seller pursuant to the Purchase Agreement" under Section 4(a)(2) exemption. This is a classic dilutive issuance structure, likely part of an M&A transaction where equity is used as consideration. The unregistered nature and reference to a Purchase Agreement indicate a material capital event affecting shareholder equity.
View raw filing on EDGAR →This press release announces a strategic partnership between OwlTing Group and Credible Finance to open cross-border payment corridors, starting with China and planned expansion to India. The disclosure highlights material operational developments: OwlPay Harbor enterprise clients have grown to 51 (up 40% since full-year 2025 results), transaction orders have doubled monthly with 103% compound monthly growth rate, and the partnership is designed to expand global payout capabilities and market reach. While not a discrete M&A transaction, this network-to-network partnership represents a significant operational and strategic milestone for the Company's payment infrastructure business.
View raw filing on EDGAR →Seadrill announced a $600 million senior unsecured notes offering by its subsidiary Seadrill Finance, intended for eligible purchasers under Rule 144A and Regulation S. While this is a material financing activity that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the M&A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The disclosure is a debt issuance announcement rather than an equity dilution or traditional M&A event, warranting classification as other_material.
View raw filing on EDGAR →Strategy Inc sold 1,732,553 shares of Class A Common Stock under its at-the-market offering program during June 8-14, 2026, generating $209.0 million in net proceeds. The company has a $21.0 billion MSTR Increase announced on March 23, 2026, with $25.7 billion remaining capacity available for issuance.
View raw filing on EDGAR →Michael P. Lyons appointed as CEO and President of Truist Financial Corporation and Truist Bank effective September 1, 2026, with base salary of $1,300,000, target AIP of 325%, and LTI awards totaling $12,000,000 for 2026 plus substantial replacement awards. William H. Rogers, Jr. retired as CEO and transitioned to Executive Chair.
View raw filing on EDGAR →The company entered into a Third Amendment to its Loan and Security Agreement, modifying material terms including extension of the interest-only period and amendment of minimum liquidity covenants. This debt restructuring creates direct financial obligations and represents a material modification to the company's capital structure.
View raw filing on EDGAR →The company announced failure of Phase 3 clinical trials (KOASTAL-2 and -3) for navacaprant in major depressive disorder, leading to discontinuation of the program. This represents a material setback to the company's pipeline and development strategy.
View raw filing on EDGAR →The company implemented a 35% reduction in force with $2 million in one-time restructuring costs and $10 million in annualized savings, triggered by discontinuation of navacaprant development. The restructuring reflects a material operational adjustment to the company's cost structure and workforce.
View raw filing on EDGAR →Sensei Biotherapeutics appointed Anand Parikh as President and Chief Executive Officer (promoted from COO), Brian Stephenson as Chief Financial Officer, and Josiah Craver as Senior Vice President of Finance and principal accounting officer, all effective June 13, 2026. Additionally, Stephen M. Hahn and Saira Ramasastry were appointed as new directors on June 12, 2026. These appointments represent material changes to the company's executive and board leadership structure.
View raw filing on EDGAR →The company amended its Certificate of Incorporation to change its name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc., with an associated ticker symbol change from SNSE to FTH, effective June 15, 2026. The name and symbol change was announced via press release and is material to investors as it affects company identification and trading.
View raw filing on EDGAR →Takis Georgakopoulos was appointed as Chief Executive Officer and Board member on June 14, 2026, following the resignation of Michael P. Lyons on June 12, 2026. The appointment includes a compensation package of $1.3M base salary, $18.6M annual equity opportunity, and $6M in promotion equity awards.
View raw filing on EDGAR →TripAdvisor entered into a put option agreement with American Express Travel Related Services on June 14, 2026, granting American Express an irrevocable commitment to acquire TheFork, TripAdvisor's online restaurant reservation and management platform in Europe, for $700 million in an all-cash transaction.
View raw filing on EDGAR →Intellia Therapeutics announced positive Phase 3 clinical trial results for lonvo-z (NTLA-2002) in hereditary angioedema, demonstrating achievement of primary and key secondary endpoints with 87% reduction in attacks (p<0.0001) and favorable safety data, supporting advancement toward anticipated 2027 U.S. launch and BLA submission.
View raw filing on EDGAR →Strategy Inc amended the Certificate of Designations for its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC), increasing dividend payment frequency from monthly to twice-monthly, and declared a conditional cash dividend on STRC at 11.50% per annum contingent upon effectiveness of the amended certificate.
View raw filing on EDGAR →enGene Therapeutics disclosed financial results for the three months ended April 30, 2026, including clinical and corporate updates, furnished via press release as Exhibit 99.1.
View raw filing on EDGAR →The company announced a board-approved workforce reduction of approximately 50% with estimated restructuring costs of $5.7–$6.4 million in cash charges and $4.7–$5.0 million in non-cash stock-based compensation, plus $1.7 million in performance-based retention bonuses, designed to preserve cash while maintaining key strategic milestones.
View raw filing on EDGAR →Chief Medical Officer Dr. Hussein Sweiti resigned effective June 14, 2026, and Chief Financial Officer Ryan Daws separated effective July 15, 2026, representing material departures of two senior executives.
View raw filing on EDGAR →Dr. William Grossman was appointed as Interim Chief Medical Officer effective June 15, 2026, and Kathleen Richton was appointed as principal financial officer, filling key C-suite positions following recent executive departures.
View raw filing on EDGAR →Item 2.02 disclosure of a press release issued on June 12, 2026 regarding "sales and earnings for its second quarter ended May 2, 2026" is a classic earnings release. The filing explicitly references quarterly financial results and attaches the press release as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →Super Micro Computer entered into an underwriting agreement on June 10, 2026 to issue and sell 75 million depositary shares representing interests in 7.00% Series A Mandatory Convertible Preferred Stock, with an additional 11.25 million shares available via an over-allotment option. The registered public offering closed on June 15, 2026, raising capital through a shelf registration statement while diluting existing shareholders.
View raw filing on EDGAR →Arcadia Biosciences entered into a securities purchase agreement on June 11, 2026, for a private placement of pre-funded warrants and investment options to purchase approximately 11.6 million shares of common stock with gross proceeds of ~$4 million. The unregistered securities were sold to accredited institutional investors under Section 4(a)(2) and Rule 506(b), with exercise prices of $0.0001 and $0.91 per share, immediate exercisability, and cashless exercise rights, representing a material dilutive equity issuance typical of PIPE-like financings.
View raw filing on EDGAR →The disclosure centers on an amendment to Jillian C. Evanko's Senior Advisor Agreement that modifies compensatory arrangements, including a termination date and fixed fee structure. While the amendment also contemplates the eventual end of her advisory services, the substantive disclosure focuses on the modification of compensation terms and conditions, making this primarily an exec_compensation event rather than a departure.
View raw filing on EDGAR →FATE Therapeutics held its Annual Meeting of Stockholders on June 12, 2026, with stockholders approving four proposals: election of three Class I Directors, ratification of Ernst & Young LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a third amendment and restatement of the 2022 Stock Option and Incentive Plan increasing available shares by 7,000,000.
View raw filing on EDGAR →